Entrada Therapeutics, Inc. (TRDA) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$4.36

From 52W high−69.93%

Volume585546.00

Market cap$187.67M

P/E (TTM)—

P/S (TTM)40.1x

Div yield—

Key dataOct 19, 2026

Open

$4.36

From 52W high

−69.93%

Volume

585546.00

Market cap

$187.67M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

34.5

MomentumView details →

1D Return

+10.30%

YTD Return

−53.97%

SummaryUpdated Jun 1, 2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a biotechnology company founded in 2016 and headquartered in Boston, Massachusetts. Originally incorporated as CycloPorters, Inc., the company changed its name to Entrada Therapeutics in October 2017 and went public in October 2021. Entrada focuses on developing innovative therapeutics for neuromuscular diseases using its proprietary endosomal escape vehicle (EEV) platform technology. The company represents an emerging player in the specialized field of intracellular drug delivery, targeting conditions where traditional therapies have struggled to achieve adequate cellular penetration.

Ask drillr about Entrada Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

2.8x

P/S (TTM)

40.1x

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

−754.72%

Net Margin

−3537.73%

EBITDA Margin

−3518.31%

ROE (TTM)

−71.02%

ROA (TTM)

−55.47%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−94.10%

EPS YoY

—

FCF YoY

−6.16%

Revenue CAGR 3Y

−55.61%

EPS CAGR 3Y

—

EBITDA YoY

−96.53%

MomentumView details →

1D Return

+10.30%

YTD Return

−53.97%

1Y Return

−24.29%

RSI (14)

34.5

vs 50D SMA

−27.65%

vs 200D SMA

−47.57%

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

10.89x

Quick Ratio

10.89x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.01

EPS Surprise

−3.72%

Beats (12Q)

5/12

Next Q EPS Est

−$0.93

Avg Surprise (4Q)

−4.05%

Rev Surprise

−61.37%

Financials snapshotView financials →

Revenue (TTM)

4.69M

Net Income (TTM)

−165.78M

Op. CF (TTM)

−134.67M

Next earningsNov 5, 2026 →

Latest newsMore news →

Entrada Therapeutics announced the recipients of its 2026 DREAMS Grant Program, awarding two $50,000 grants to support projects addressing healthcare disparities in the Duchenne muscular dystrophy community.40d ago

Similar companies

PepGen Inc.PEPG Akebia Therapeutics, Inc.AKBA Sutro Biopharma, Inc.STRO Compugen Ltd.CGEN ProQR Therapeutics N.V.PRQR Evommune, Inc.EVMN Find similar companies →

Latest newsMore news →

Entrada Therapeutics said the independent Data Monitoring Committee recommended initiating Cohort 3 of the ELEVATE-44-201 study at 18 mg/kg after reviewing safety and pharmacokinetic data from eight Cohort 2 participants.6d ago Entrada Therapeutics announced the recipients of its 2026 DREAMS Grant Program, awarding two $50,000 grants to support projects addressing healthcare disparities in the Duchenne muscular dystrophy community.40d ago